bims-myxlip 2024-03-31 papers

Issue of 2024‒03‒31
three papers selected by
Laura Mannarino, Humanitas Research

Virchows Arch. 2024 Mar 28.

Nuclear morphological atypia in biopsy accurately reflects the prognosis of myxoid liposarcoma.

Kengo Kawaguchi, Kenichi Kohashi, Takeshi Iwasaki, Taro Mori, Hiroshi Furukawa, Chiaki Sato, Hiroki Sonoda, Sakura Shiraishi, Makoto Endo, Yasuharu Nakashima, Yoshinao Oda.

Currently, it is difficult to predict the prognosis of myxoid liposarcoma (MLS) in biopsy specimens. In this study, we determined whether nuclear morphology may be used to predict the prognosis of MLS in primary biopsy specimens. Two pathologists evaluated nuclear morphology using the modified WHO/ISUP and Fuhrman grades. Survival analyses were performed by grouping nuclear high- and low-grades. We examined 53 MLS cases, which included 29 (54.7%) male and 24 (45.3%) female patients with a median age of 46 years (interquartile range, 37 - 60). In total, 7 (13.2%) and 16 (30.2%) cases were assigned to the high nuclear grade group based on the modified WHO/ISUP and Fuhrman gradings, respectively. Survival analyses revealed a significantly worse disease-free survival in the high-grade group (hazard ratio (HR), 7.51; 95% confidence interval (CI), 2.67-21.1, p < 0.001 by the modified WHO/ISUP grading; HR, 4.45; 95% CI, 1.63-12.1, p = 0.001 by the modified Fuhrman grading). Moreover, the modified WHO/ISUP grade showed a significantly worse overall survival in the high-grade group (HR, 4.39; 95% CI, 1.04-18.6, p = 0.028), and the modified Fuhrman grade exhibited a similar, but not significant, trend. Our results indicate that nuclear morphology grading is a good predictor of patient prognosis at the time of biopsy in MLS. Even when cell density is sparse, treatment strategies should be carefully considered when individual tumor cells exhibit atypical nuclei.

Keywords: Morphology; Myxoid liposarcoma; Nuclear atypia; Sarcoma

DOI: https://doi.org/10.1007/s00428-024-03796-7

Clin Cancer Res. 2024 Mar 27.

Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.

Jiangang Liu, David S Moura, Robin L Jones, Amit Aggarwal, Ebert J Philip, Andrew J Wagner, Jennifer Wright, Javier Martín-Broto, William D Tap.

PURPOSE: This exploratory analysis evaluated the tumor samples of the patients treated with doxorubicin (with or without olaratumab) in a negative phase-3 ANNOUNCE trial to better understand the complexity of advanced soft tissue sarcomas (STS) and to potentially identify its predictive markers.EXPERIMENTAL DESIGN: RNA sequencing was performed on pretreatment tumor samples (n=273) from the ANNOUNCE trial to evaluate response patterns and identify potential predictive treatment markers for doxorubicin. A BOR-associated signature to doxorubicin (REDSARC) was created by evaluating tumors with radiographic response versus progression. An external cohort of doxorubicin-treated patients from the Spanish Group for Research on Sarcomas (GEIS) was utilized for refinement and validation.
RESULTS: A total of 259 samples from the trial were considered for analysis. Comparative analyses by the treatment arm did not explain the negative trial. However, there was an association between the BOR signature and histologic subtype (χ2 P=2.0e-7) and grade (P=0.002). There were no associations between the BOR signature and gender, age, ethnicity or stage. Applied to survival outcomes, REDSARC was also predictive for progression-free (PFS) and overall survival (OS). Using the GEIS cohort, a refined 25-gene signature was identified and applied to the ANNOUNCE cohort, where it was predictive of PFS and OS in leiomyosarcoma, liposarcoma, and other sarcoma subtypes, but not in undifferentiated pleomorphic sarcoma.
CONCLUSIONS: The refined REDSARC signature provides a potential tool to direct the application of doxorubicin in sarcomas and other malignancies. Validation and further refinement of the signature in other potentially subtype specific prospective cohorts is recommended.

DOI: https://doi.org/10.1158/1078-0432.CCR-23-3936

Indian J Surg Oncol. 2024 Mar;15(Suppl 1): 19-21

Mandibular Myxoid Liposarcoma: a Case Study.

Jorge Arturo Barreras-Espinoza, Pamela Estefanía López-Uribe, Francisco Alberto Leyva-Moraga, Fernando Leyva-Moraga, Eduardo Leyva-Moraga, Jesús Antonio Ocejo-Gallegos, Martín Armando Burrola-Suárez, Mónica I Burgos-Claudio, Martha María Llanez-Grijalva, Ulises Martínez-Legorreta.

Liposarcomas are described as soft tissue sarcomas derived from adipose tissue. The finding of this tumor in the mandibular region is exceedingly rare. As of now, it has been described mainly in case reports and small series. A multidisciplinary approach is required to offer optimal treatment and may involve surgery, radiation and systemic therapies. Surgical repair of these defects represents a major challenge in oral and maxillofacial reconstructive surgery. We present the case of a 54-year-old man referred to our center with a progressively increasing mass in the anterior portion of the mandible. Biopsy revealed a well-differentiated myxoid liposarcoma. Resection of the tumor was performed with an additional primary reconstruction.

Keywords: Liposarcoma; Mandibular reconstruction; Microsurgery; Myxoid liposarcoma; Reconstructive surgical procedures; Soft tissue neoplasms

DOI: https://doi.org/10.1007/s13193-023-01705-z